Scientific program

« LA JOURNÉE DU PRÉSIDENT DE LA SFN »MULTIPLE SCLEROSIS : 25 YEARS LATER !

SCLÉROSE EN PLAQUES : 25 ANS APRÈS ...

December 7 th 2017LE COUVENT DES JACOBINS, CENTRE DES CONGRÈS DE RENNES

Coordinator : Gilles Edan

8H45 : INTRODUCTIONby Gilles Edan (Président de la Société Française de Neurologie)

> 9H00-9H30 : Pr Fred Lublin (New York) - chair by Pr Thibault Moreau (Dijon)1996 and 2013 Multiple Sclerosis phenotypic classifications : how much accurate and useful are they ?

> 9H30-10H00 : Pr Helen Tremlett (Vancouver) - chair by Pr Sandra Vukusic (Lyon)Epidemiological studies of the history of multiple sclerosis : how much have they changed our views on MS for the last 25 years?

> 10H00-10H30 : Pr Alastair Compston (Cambridge) - chair by Pr Bertrand Fontaine (Paris)The International MS Genetics Consortium studies : do we better understand the role of genetic susceptibi-lity in MS ?

> 11H00-11H30 : Pr Peter Hartung (Dusseldorf) - chair by Pr David Laplaud (Nantes)Understanding immune dysfunctions : emergence of concepts for treating and monitoring MS patients ?

> 11H30-12H00 : Pr Hans Lassman (Vienne) - chair by Pr Bruno Stankoff (Paris)Brain tissue pathology : new concepts for the understanding of MS lesions. > 12H00-12H30 : Pr Catherine Lubetzki (Paris) - chair by Pr Roland Liblau (Toulouse)Brain tissue repair : new concepts for the understanding of remyelination processes in multiple sclerosis ?

> 14H00-14H30 : Pr David Miller (Londres) - chair by Pr Jean Pelletier (Marseille)25 years of imaging techniques : do we better understand the progression of tissue injury in brain and spinal cord ?

> 14H30-15H00 : Pr Ludwig Kappos (Basel) - chair by Pr Marc Debouverie (Nancy)25 years methodological changes in trial designs : an adequate assessment of efficacy and safety of therapeutic agents in MS ?

> 15H00-15H30 : Pr Michel Clanet (Toulouse) - chair by Pr Pierre Clavelou (Clermont Ferrand)25 years of a changing care system : have we improved MS patients daily care ?

> 16H00-16H30 : Pr Mar Tintoré (Barcelone) - chair by Pr Emmanuelle Leray (Rennes)Clinical and MRI predictors : which impact on disability progression and treatment monitoring ? > 16H30-17H00 : Pr Per Sorensen (Copenhagen) - chair by Pr Joel Oger (Vancouver)Biological biomarkers : which impact on disability progression treatment monitoring ?

> 17H00-17H30 : Pr Giancarlo Comi (Milan) - chair by Pr Jérome De Seze (Strasbourg)Lessons from 25 years use of approved DMT drugs : which impact on therapeutic strategy for 2018 ?

17H30-17H45 : CONCLUSION / TAKE HOME MESSAGESChristine Lebrun (Nice) and Patrick Vermersch (Lille)

SESSION 1 : CLINICAL, EPIDEMIOLOGICAL AND GENETIC SUSCEPTIBILITY IN MS Chair persons : Emmanuelle Le Page and Jean-Yves Delattre

SESSION 2 : IMMUNE AND PATHOLOGICAL CONCEPTS IN MS

SESSION 3 : NEW PARADIGMS IN MS

SESSION 4 : MONITORING MS OVER THE LAST 25 YEARS

Chair persons : Bruno Brochet and Christine Tranchant

Chair persons : Anne Kerbrat and Bruno Dubois

Chair persons : Marc Coustans and Didier Leys

Michel Clanet, ToulousePierre Clavelou, Clermont FerrandGiancarlo Comi, MilanAlastair Compston, CambridgeMarc Coustans, QuimperJérome De Seze, StrasbourgMarc Debouverie, NancyGilles Edan, RennesBertrand Fontaine, ParisPeter Hartung, DusseldorfLudwig Kappos, BaselAnne Kerbrat, RennesDavid Laplaud, NantesHans Lassman, VienneEmmanuelle Le Page, Rennes

Christine Lebrun, NiceEmmanuelle Leray, RennesRoland Liblau, ToulouseCatherine Lubetzki, ParisFred Lublin, New YorkDavid Miller, LondresThibault Moreau, DijonJoel Oger, VancouverJean Pelletier, MarseillePer Sorensen, CopenhagenBruno Stankoff, ParisMar Tintoré, BarceloneHelen Tremlett, VancouverSandra Vukusic, LyonPatrick Vermersch, Lille

SPEAKERS AND CHAIR-PERSONS